Your Dossier Has 300 Pages. The Payer Has Four Questions.

One of you left the room confused — and it was not the payer.

Every year, the pharmaceutical industry spends hundreds of millions on market access infrastructure: pricing committees, HEOR modelling teams, value dossier specialists, reimbursement consultants, advisory boards with former payer panellists, and endless internal alignment meetings. The output is enormous. The alignment with what payers actually want to know is, consistently, poor.

This is not a knowledge problem. It is a framing problem.

Payers — whether they sit in the G-BA, the Transparency Committee, NICE, AIFA, a regional access body, or a US formulary committee — do not evaluate your product through the same 47-dimension value framework used inside the company. They do not read your dossier the way you wrote it. They are not waiting for your value story to unfold in the order your internal teams assembled it.

They ask four questions.

Do I have a problem? Do I need a solution? Does your solution work? Can I afford it?

If you cannot answer those four questions clearly, sequentially, and in payer language, the quality of your evidence may not save you. You have not necessarily failed on data. You have failed on architecture.

And in market access, architecture is strategy.

This is the burden question.

Before a payer evaluates your molecule, they evaluate whether the disease you are targeting constitutes a problem for their system. Not for the patient in the abstract. Not for the medical community. Not for the global burden of disease literature. For their budget, their population, their political environment, and the service they are expected to manage.

The distinction matters more than most launch teams realise. A disease can be devastating at the individual level and almost invisible at the system level. Rare diseases may carry enormous per-patient burden but limited aggregate budget impact. Common conditions may affect millions but sit in therapeutic areas where payers see managed costs, generic saturation, and no obvious crisis requiring intervention.

The industry often assumes that clinical severity automatically creates payer urgency. It does not. A payer’s definition of “problem” is epidemiological, economic, and politically visible — in that order. How many people are affected? How much does it cost the system today? Is the pressure visible enough that someone is being asked to act?

If the answer to those questions is weak, your product enters the conversation at a disadvantage that even a strong Phase 3 result may struggle to overcome.

The first question is not about your drug. It is about whether the payer believes they need one.

This is the unmet need question. And it is more specific than it sounds.

The payer is not asking whether better treatments could exist in theory. They are asking whether the current standard of care is failing badly enough to justify the disruption of adding a new product to the pathway.

That word matters: disruption.

A payer already has a treatment pathway. It may be imperfect, outdated, inconvenient, clinically limited, or associated with suboptimal outcomes. But it exists. It has a known cost. It is operationally embedded. Clinicians know how to use it. Procurement teams know how to buy it. Budgets know how to absorb it.

Your product must not merely be better. It must be better enough to justify the switching cost: clinical, administrative, behavioural, budgetary, and political.

This is where industry communication often breaks down. Launch teams present unmet need as a medical narrative: patients suffer, outcomes remain poor, disease progression continues, quality of life is impaired. Payers translate that narrative instantly into a different question: what is the incremental difference over what I already fund?

The gap between “patients need better options” and “my system needs to pay for a new option” is where many access strategies die. Not because the need is not real. Because the need was articulated in medical language while the payer was listening in economic language.

A poor standard of care is not automatically a reimbursable gap. A convenience benefit is not automatically a pricing argument. A new formulation is not automatically a new value proposition.

The payer is not asking whether the world could be better. They are asking whether this specific system needs to change.

This is the clinical value question.

Paradoxically, it is the question the industry is best prepared to answer — and one of the questions it most often answers badly. Not because the data are necessarily weak, but because the data are often presented in the wrong frame.

Regulators and payers do not ask the same question. The FDA and EMA ask whether the product is safe, efficacious, and approvable. The payer asks whether the product is more valuable than the comparator their system currently funds, in the population they actually treat, over the time horizon that matters for their decision.

That difference is not semantic. It is the difference between approval and access.

A placebo-controlled trial may win regulatory approval and still leave the HTA body asking for active comparator evidence. A highly selected pivotal population may support a label and still raise doubts about generalisability. A response endpoint may demonstrate biological activity and still fail to answer the payer’s question about survival, quality of life, resource use, or cost-effectiveness.

This is why comparator mismatch remains one of the most predictable failures in HTA submissions. The pivotal trial used placebo; the payer wants the reimbursed standard of care. The trial population was clean; the payer treats patients with comorbidities, prior treatment exposure, adherence problems, and clinical complexity. The primary endpoint was clinically meaningful to investigators; the payer wants to know whether that endpoint changes outcomes they are willing to pay for.

Every experienced market access professional knows this. And yet, year after year, companies arrive at NICE, the G-BA, the Transparency Committee, AIFA, and other payer bodies with clinical packages built for regulatory approval and retrofitted for reimbursement.

That is the wrong sequence.

HTA cannot be reverse-engineered properly at the end of development. It has to be designed into the evidence strategy from the beginning.

The question is not simply whether your solution works. The question is whether your evidence proves it works better than what the payer already has — in the terms the payer uses to define “better.”

This is the economic value question. And it is the question that determines whether the previous three answers matter.

A payer can acknowledge the burden, recognise the unmet need, accept the clinical benefit — and still say no. Because the price exceeds the system’s willingness to pay. Because the five-year budget impact is too high. Because the cost per QALY sits above the relevant threshold. Because the uncertainty is too large. Because the opportunity cost is too visible.

The industry often treats pricing as a negotiation that happens after the value story has been told. Payers treat price as the filter through which every value claim is evaluated.

These two perspectives collide in every HTA submission, every AMNOG negotiation, every NICE committee meeting, every formulary discussion, and every confidential discount negotiation.

The payer does not ask “can I afford it?” in isolation. They ask: given the burden, given the unmet need, given the clinical evidence, and given the uncertainty — is the price proportionate to the incremental value this product delivers over what I already fund?

That is why the four questions are sequential, not parallel. Each one gates the next.

A product addressing a high-burden condition, with clear unmet need, strong comparative evidence, and meaningful patient benefit can justify a different pricing conversation. A product with moderate burden, modest unmet need, uncertain comparative evidence, and incremental benefit cannot simply borrow the language of breakthrough innovation and expect the system to pay breakthrough prices.

Innovation is not the argument. Proportionate value is the argument.

And price is where every unsupported claim becomes visible.

Market access teams know these questions exist. Every HEOR professional can recite them. Every pricing lead understands them. Every experienced medical affairs team has seen them emerge in advisory boards, payer research, HTA feedback, or reimbursement negotiations.

The problem is not awareness. The problem is that the organisational architecture of the pharmaceutical industry is not built around answering them.

Medical affairs owns the disease burden narrative. HEOR owns the economic model. Clinical development owns the trial data. Pricing owns the number. Four departments. Four workstreams. Four timelines. Four versions of value.

The payer, however, does not experience value in silos.

The payer sits across the table and asks four questions in order. The industry responds with four answers from four departments, often assembled late in the process, formatted into a dossier, and presented as if proximity were the same as coherence.

It is not.

A burden narrative that does not lead naturally into unmet need is not a strategy. An unmet need claim that is not supported by comparative evidence is not a strategy. A clinical value story disconnected from the economic model is not a strategy. A price that does not reflect the strength, uncertainty, and relevance of the evidence is not a strategy.

It is a collection of workstreams.

And payers can see the joins.

That is the structural failure of pharmaceutical market access: not that companies lack evidence, expertise, or investment, but that they often lack a single integrated payer-facing logic.

Four questions. Asked in sequence. Answered in silos.

No amount of evidence generation will fix a narrative architecture problem.

Before you negotiate with a payer, answer the four questions they will ask.

Not in the order your company is organised.

In the order the payer decides.

Share

Beyond Approval publishes weekly strategic intelligence on market access, HTA, pricing, and regulatory shifts that reshape how medicines reach patients — written from inside the industry, for the people whose decisions move drugs to patients.